West Pharmaceutical Services (WST) raised its full-year organic revenue growth forecast and expanded its margin outlook, driven by strong demand for high-value product components and a surging pipeline of European regulatory projects.
The company said its second-quarter organic revenue exceeded expectations by $35 million, representing a 4.2% beat. Full-year organic revenue growth guidance was raised to 10%-11%, up from 7%-9%, marking a midpoint increase of 250 basis points. Margin expansion guidance was also lifted to more than 200 basis points for the year, approaching 250 basis points—about 50 basis points above prior estimates.
High-value product (HVP) components are expected to contribute more than eight percentage points to the growth forecast. The segment grew in the high teens during the quarter and now accounts for more than 50% of total revenue. Standard products, which make up roughly 20% of revenue, grew 1% in the period.
Asia-Pacific was a standout region, with organic growth exceeding 25% in the quarter, cited at 27%. The company noted that new regional leadership has been in place for approximately nine months.
West holds more than 70% global market share in elastomer components and participates in greater than 90% of biologics projects. A key growth driver is the European Annex 1 regulatory opportunity, estimated at $6 billion total. West has penetrated about $1 billion of that addressable market, with active Annex 1 projects approaching 800—roughly 50% higher than a year earlier. The company estimates the Annex 1 opportunity will contribute an incremental 200 basis points of growth to the total business.
GLP-1-related revenue represents about 10% of elastomer-side revenues, while West Vantage accounted for approximately 17% of quarterly revenue. On the GLP-1 front, management expressed continued optimism, noting the market remains in early stages of penetration both in the U.S. and globally.
On the expense and investment side, West plans capital expenditures of approximately $250 million for the year, equal to 6%-8% of revenue. The company repurchased $450 million of stock in the first half of 2024 against a $1 billion authorization. Drug Handling Solutions is expected to generate $20 million in total for 2024, ramping to more than $60 million at full maturity in 2028.
West is exiting an $80 million annual continuous glucose monitoring contract, which will reduce revenue by $20 million in each of the third and fourth quarters.
Shares of West Pharmaceutical Services traded at $336.94, with a market capitalization of $23.7 billion. The stock has surged 44% over the past six months.
Bob Ingman, chief financial officer, told attendees at the Wells Fargo 21st Annual Healthcare Conference on September 10 that "we are the market leader and really serving a critical role within the pharmaceutical supply chain." He added that the biggest contributor to growth was non-GLP-1 HVP demand, supported by the continued rise of biologics and regulatory requirements around Annex 1.
